Brian Mueller - 29 Apr 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Financial Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
29 Apr 2022
Net transactions value
-$533,854
Form type
4
Filing time
06 May 2022, 19:45:49 UTC
Previous filing
17 Mar 2022
Next filing
01 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21,218 +340 +0.89% $62.41 38,639 29 Apr 2022 Direct F1
transaction BMRN Common Stock Options Exercise $76,343 +2,038 +5.3% $37.46 40,677 04 May 2022 Direct F2
transaction BMRN Common Stock Sale $172,211 -2,038 -5% $84.50 38,639 04 May 2022 Direct F2
transaction BMRN Common Stock Options Exercise $365,685 +9,762 +25% $37.46 48,401 04 May 2022 Direct F2
transaction BMRN Common Stock Sale $824,889 -9,762 -20% $84.50 38,639 04 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -2,038 -100% $0.000000* 0 04 May 2022 Common Stock 2,038 $37.46 Direct F2, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -9,762 -100% $0.000000* 0 04 May 2022 Common Stock 9,762 $37.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on March 14, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.